The Andalusia-Roche Alliance has recently launched a groundbreaking research project aimed at advancing personalized medicine in neurological diseases. The project, titled ‘Personalized medicine in neurological diseases through the application of biomarkers to improve the diagnosis, prognosis and treatment of the patient,’ has already begun recruiting patients in recent weeks.
Led by Pedro Serrano, head of the Neurology service at the Regional University Hospital of Málaga, and Ibima-Bionand researcher Begoña Oliver, the project aims to focus on diseases such as Alzheimer’s and Parkinson’s. The goal is to advance early diagnosis and therapeutic alternatives for these types of pathologies.
The research team, which includes clinical and basic researchers from 13 SSPA hospitals based in the eight Andalusian provinces, is working to develop scientific methodologies and techniques for the determination of molecular and neuroimaging biomarkers, as well as neuropsychological tools.
The Andalusia-Roche Alliance, a public-private initiative, is also supporting the project by incorporating new scientific-technical services for the detection of biomarkers. These technologies were previously outsourced outside the Andalusian community but are now available to all members of the Alliance, Neuro-RECA, and the rest of the scientific community for the detection of biomarkers by SIMOA and the detection of neuroglial antibodies, essential for improving the diagnosis of neurological diseases.
The initiative is supported by about twenty neuroscience professionals from different provinces of Andalusia. It aims to develop research projects that will allow the implementation of personalized medicine in the field of neurology. The project has already mobilized investments of around one million euros and aims to deepen the knowledge of neurological diseases, with a focus on public-private collaboration and a vocation for continuity.